Publicité
English Flag
Biotech Finances - L'information stratégique des biodécideurs et des bioinvestisseurs
RECHERCHER SUR LE SITE
ET DANS LES ARCHIVES
lundi 20 mai 2013
 Mémoriser  
 
 

Communiqué de Presse

Research and Markets: Global Malignant Melanoma Drug Pipeline Capsule - 2012

Le 11/05/2012 à 15:05

May 11, 2012 13:40 UTC

Research and Markets: Global Malignant Melanoma Drug Pipeline Capsule - 2012

DUBLIN--(BUSINESS WIRE)-- Dublin - Research and Markets (http://www.researchandmarkets.com/research/6jtw3v/global_malignant_m) has announced the addition of the "Global Malignant Melanoma Drug Pipeline Capsule - 2012" report to their offering.

Fore Pharma's latest report Global Malignant Melanoma Drug Pipeline Capsule - 2012' is an outline of all the key research and development (R&D) activities of the global Malignant Melanoma drug market. It covers information on key pipeline molecules in various stages of R&D including all the phases of clinical trials, preclinical research, and drug discovery. The report is up-to-date with full coverage of the licensing activities and partnerships.

This report helps executives to keep a track of their competitors and understand their pipeline molecules. The information presented in this report can be used for identifying the partners, prioritizing, evaluating opportunities, developing business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company and mechanism of action across the different stages of R&D. It includes registered / preregistered stage, phase 3 clinical trial, phase 2 clinical trial, phase 1 clinical trial, preclinical research, and drug discovery. It also provides information on pipeline molecules developed in leading geographies including the U.S., Canada, France, Germany, U.K., Italy, and Spain by various stages of R&D. Licensing activities and partnerships in the Malignant Melanoma drug market is thoroughly covered by company and licensee with the deal summary.

Key Features of the Report:

- Malignant Melanoma: Overview

- Malignant Melanoma Drug Pipeline Overview

- Malignant Melanoma Phase 3 Clinical Trial Drug Pipeline Insights

- Malignant Melanoma Phase 2 Clinical Trial Drug Pipeline Insights

- Malignant Melanoma Phase 1 Clinical Trial Drug Pipeline Insights

- Malignant Melanoma Preclinical Research Drug Pipeline Insights

- Malignant Melanoma Drug Discovery Pipeline Insights

- Geographic Landscape of Malignant Melanoma R&D Activities

- Malignant Melanoma R&D Activities in North America

- Malignant Melanoma R&D Activities in Europe

- Licensing Activities / Partnerships in the Global Malignant Melanoma Drug Market

For more information visit http://www.researchandmarkets.com/research/6jtw3v/global_malignant_m

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): 353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals


Source: Research and Markets